| Lyndsay Whitlock, PT, DPT | |
|
1547 Bypass Rd, Winchester, KY 40391-2714 | |
| (859) 744-4411 | |
| Not Available |
| Full Name | Lyndsay Whitlock |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 6 Years |
| Location | 1547 Bypass Rd, Winchester, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477034262 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 007687 (Kentucky) | Primary |
| 225100000X | Physical Therapist | 043515 (New York) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baptist Health Medical Group Inc | 5597867184 | 1912 |
News Archive
GE Healthcare and Vanderbilt University Medical Center today announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will be developed to help predict both the efficacy of an immunotherapy treatment and its adverse effects for a specific patient before the therapy is administered.
A Baylor University study has found that a popular nutritional supplement that is marketed to lead to greater muscle strength through increasing blood flow to the muscle does not increase blood flow as claimed on the bottle.
Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.
New research indicates that giving patients a continuous low dose of an immune system booster, a method known as metronomic dosing, as part of a therapeutic prostate cancer vaccine strategy is safe and produces similar immune responses and fewer side effects than the more common dosing method, which is not well tolerated by many patients. This study, led by researchers at that National Cancer Institute (NCI), part of the National Institutes of Health, was published in the Aug. 15, 2008, issue of Clinical Cancer Research.
Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.
› Verified 3 days ago
| Provider Name | Baptist Health Medical Group Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1740586213 PECOS PAC ID: 5597867184 Enrollment ID: O20070228000503 |
News Archive
GE Healthcare and Vanderbilt University Medical Center today announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will be developed to help predict both the efficacy of an immunotherapy treatment and its adverse effects for a specific patient before the therapy is administered.
A Baylor University study has found that a popular nutritional supplement that is marketed to lead to greater muscle strength through increasing blood flow to the muscle does not increase blood flow as claimed on the bottle.
Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.
New research indicates that giving patients a continuous low dose of an immune system booster, a method known as metronomic dosing, as part of a therapeutic prostate cancer vaccine strategy is safe and produces similar immune responses and fewer side effects than the more common dosing method, which is not well tolerated by many patients. This study, led by researchers at that National Cancer Institute (NCI), part of the National Institutes of Health, was published in the Aug. 15, 2008, issue of Clinical Cancer Research.
Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.
› Verified 3 days ago
| Provider Name | Kentucky Orthopedic Rehabilitation Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1093715054 PECOS PAC ID: 0345157293 Enrollment ID: O20090211000813 |
News Archive
GE Healthcare and Vanderbilt University Medical Center today announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will be developed to help predict both the efficacy of an immunotherapy treatment and its adverse effects for a specific patient before the therapy is administered.
A Baylor University study has found that a popular nutritional supplement that is marketed to lead to greater muscle strength through increasing blood flow to the muscle does not increase blood flow as claimed on the bottle.
Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.
New research indicates that giving patients a continuous low dose of an immune system booster, a method known as metronomic dosing, as part of a therapeutic prostate cancer vaccine strategy is safe and produces similar immune responses and fewer side effects than the more common dosing method, which is not well tolerated by many patients. This study, led by researchers at that National Cancer Institute (NCI), part of the National Institutes of Health, was published in the Aug. 15, 2008, issue of Clinical Cancer Research.
Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lyndsay Whitlock, PT, DPT 1547 Bypass Rd, Winchester, KY 40391-2714 Ph: (859) 744-4411 | Lyndsay Whitlock, PT, DPT 1547 Bypass Rd, Winchester, KY 40391-2714 Ph: (859) 744-4411 |
News Archive
GE Healthcare and Vanderbilt University Medical Center today announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will be developed to help predict both the efficacy of an immunotherapy treatment and its adverse effects for a specific patient before the therapy is administered.
A Baylor University study has found that a popular nutritional supplement that is marketed to lead to greater muscle strength through increasing blood flow to the muscle does not increase blood flow as claimed on the bottle.
Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.
New research indicates that giving patients a continuous low dose of an immune system booster, a method known as metronomic dosing, as part of a therapeutic prostate cancer vaccine strategy is safe and produces similar immune responses and fewer side effects than the more common dosing method, which is not well tolerated by many patients. This study, led by researchers at that National Cancer Institute (NCI), part of the National Institutes of Health, was published in the Aug. 15, 2008, issue of Clinical Cancer Research.
Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.
› Verified 3 days ago
David Blake Jackson, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 273 Shoppers Dr, Winchester, KY 40391 Phone: 859-745-7995 Fax: 859-745-0115 | |
Cassandra Neary, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 175 Hospital Dr, Winchester, KY 40391 Phone: 859-745-3500 | |
Jenifer Long, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 175 Hospital Dr, Winchester, KY 40391 Phone: 859-745-3500 | |
Christopher R. Sharrock, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1932 Bypass Rd, Winchester, KY 40391 Phone: 859-749-4039 Fax: 859-757-0088 | |
Cameron Fulcher, P.T., D.P.T Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1547 Bypass Rd, Winchester, KY 40391 Phone: 859-744-4411 Fax: 859-744-1611 | |
Summit Physical Therapy, Pllc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 126 Professional Ave, Winchester, KY 40391 Phone: 859-737-3994 Fax: 859-737-3223 | |
Drayer Physical Therapy Institute Of Kentucky Pllc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 160 Pedro Way, Winchester, KY 40391 Phone: 859-745-2152 Fax: 859-745-2153 |